Perceived access to opioid agonist treatment in prison among people with a history of injection drug use: A qualitative study.

[1]  T. Rhodes,et al.  Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot. , 2022, The International journal on drug policy.

[2]  C. Aitken,et al.  High rates of resumption of injecting drug use following release from prison among men who injected drugs before imprisonment , 2022, Addiction.

[3]  J. Rehm,et al.  Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study , 2022, BMC Public Health.

[4]  C. Treloar,et al.  "It's a revolving door": Ego-depletion among prisoners with injecting drug use histories as a barrier to post-release success , 2022, International Journal of Drug Policy.

[5]  J. Rich,et al.  Switching of opioid agonist treatment modality during imprisonment: A novel marker for increased support need during and following release from prison. , 2022, The International journal on drug policy.

[6]  Peter B. Jones,et al.  Qualitative study of candidacy and access to secondary mental health services during the COVID-19 pandemic , 2022, Social Science & Medicine.

[7]  Maria del Mar Quiroga,et al.  Cohort Profile: The Melbourne Injecting Drug User Cohort Study (SuperMIX). , 2021, International journal of epidemiology.

[8]  F. Altice,et al.  Multi-level implementation factors that influence scale-up of methadone maintenance treatment in Moldovan prisons: A qualitative study , 2021, Journal of Substance Abuse Treatment.

[9]  C. Treloar,et al.  Structural competency in the post-prison period for people who inject drugs: A qualitative case study. , 2021, The International journal on drug policy.

[10]  F. Altice,et al.  Decisional considerations for methadone uptake in Kyrgyz prisons: The importance of understanding context and providing accurate information. , 2021, The International journal on drug policy.

[11]  C. Oldmeadow,et al.  Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings , 2020, Addiction.

[12]  G. Horvath,et al.  The state of harm reduction in prisons in 30 European countries with a focus on people who inject drugs and infectious diseases , 2020, Harm Reduction Journal.

[13]  S. Haw,et al.  A systematic review of qualitative evidence on barriers to and facilitators of the implementation of opioid agonist treatment (OAT) programmes in PRISONS. , 2020, The International journal on drug policy.

[14]  Joanne Neale,et al.  ITERATIVE CATEGORISATION (IC) (PART 2): INTERPRETING QUALITATIVE DATA. , 2020, Addiction.

[15]  S. Ward,et al.  Rapid upscale of depot buprenorphine (CAM2038) in custodial settings during the early COVID-19 pandemic in New South Wales, Australia. , 2020, Addiction.

[16]  Christy K. Scott,et al.  A Scoping Review of Barriers and Facilitators to Implementation of Medications for Treatment of Opioid Use Disorder within the Criminal Justice System. , 2020, The International journal on drug policy.

[17]  S. Baggio,et al.  The Accessibility of Opioid Agonist Treatment and Its Forced Discontinuation in Swiss Prisons—Attitudes, Perceptions and Experiences of Defense Lawyers in Dealing With Detained Persons Using Opioids , 2020, Frontiers in Psychiatry.

[18]  G. Dore,et al.  Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting. , 2020, The International journal on drug policy.

[19]  K. Seear,et al.  "A spray bottle and a lollipop stick": An examination of policy prohibiting sterile injecting equipment in prison and effects on young men with injecting drug use histories. , 2020, The International journal on drug policy.

[20]  P. Crits-Christoph,et al.  Trust and respect in the patient-clinician relationship: preliminary development of a new scale , 2019, BMC psychology.

[21]  S. Bonato,et al.  Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review , 2019, PLoS medicine.

[22]  Graeme Henderson,et al.  Global patterns of opioid use and dependence: harms to populations, interventions, and future action , 2019, The Lancet.

[23]  T. Dobbins,et al.  The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study , 2019, The Lancet. Public health.

[24]  Nanor Minoyan,et al.  Conceptualising access in the direct-acting antiviral era: An integrated framework to inform research and practice in HCV care for people who inject drugs. , 2019, The International journal on drug policy.

[25]  C. Aitken,et al.  The Prison and Transition Health (PATH) Cohort Study: Study Protocol and Baseline Characteristics of a Cohort of Men with a History of Injecting Drug Use Leaving Prison in Australia , 2019, Journal of Urban Health.

[26]  E. McGlynn,et al.  A Framework for Increasing Trust Between Patients and the Organizations That Care for Them , 2019, JAMA.

[27]  T. Douglas,et al.  The Case against Forced Methadone Detox in the US Prisons , 2016, Public health ethics.

[28]  Josephine G. Walker,et al.  Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis , 2018, The Lancet. Infectious diseases.

[29]  T. Wild,et al.  A policy analysis exploring hepatitis C risk, prevention, testing, treatment and reinfection within Australia’s prisons , 2018, Harm Reduction Journal.

[30]  Caroline C. Johnson,et al.  Beyond the walls: Risk factors for overdose mortality following release from the Philadelphia Department of Prisons. , 2018, Drug and alcohol dependence.

[31]  C. Treloar,et al.  ‘Fighting a losing battle’: prisoners’ perspectives of treatment as prevention for hepatitis C with inadequate primary prevention measures , 2018, Drugs: Education, Prevention and Policy.

[32]  P. Webster.  Canada reveals needle exchange programme in prisons , 2018, The Lancet.

[33]  J. Lazarus,et al.  Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries , 2018, Harm Reduction Journal.

[34]  F. Luciani,et al.  Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study. , 2018, The International journal on drug policy.

[35]  C. Treloar,et al.  Who goes first? Understanding hepatitis C risk among injecting networks in the prison setting. , 2018, Drug and alcohol dependence.

[36]  J. Leung,et al.  Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review , 2017, The Lancet. Global health.

[37]  J. Strang,et al.  High risk of overdose death following release from prison: variations in mortality during a 15‐year observation period , 2017, Addiction.

[38]  S. Fazel,et al.  Substance use disorders in prisoners: an updated systematic review and meta‐regression analysis in recently incarcerated men and women , 2017, Addiction.

[39]  K. Dolan,et al.  A qualitative study of reasons for seeking and ceasing opioid substitution treatment in prisons in New South Wales, Australia , 2017, Drug and alcohol review.

[40]  M. Farrell,et al.  Yes, people can die from opiate withdrawal. , 2017, Addiction.

[41]  F. Altice,et al.  The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia , 2016, The Lancet.

[42]  C. Treloar,et al.  The Prison Economy of Needles and Syringes: What Opportunities Exist for Blood Borne Virus Risk Reduction When Prices Are so High? , 2016, PloS one.

[43]  Joanne Neale,et al.  Iterative categorization (IC): a systematic technique for analysing qualitative data , 2016, Addiction.

[44]  Kristian Mjåland.  Exploring prison drug use in the context of prison-based drug rehabilitation , 2016 .

[45]  C. Treloar,et al.  Trust and people who inject drugs: The perspectives of clients and staff of Needle Syringe Programs. , 2016, The International journal on drug policy.

[46]  R. Mattick,et al.  The extramedical use and diversion of opioid substitution medications and other medications in prison settings in Australia following the introduction of buprenorphine-naloxone film. , 2016, Drug and alcohol review.

[47]  Kristian Mjåland.  The paradox of control: An ethnographic analysis of opiate maintenance treatment in a Norwegian prison. , 2015, The International journal on drug policy.

[48]  J. Wong,et al.  Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial , 2015, The Lancet.

[49]  E. Wood,et al.  Withdrawal from methadone in US prisons: cruel and unusual? , 2015, The Lancet.

[50]  C. Treloar,et al.  Acquiring hepatitis C in prison: the social organisation of injecting risk , 2015, Harm Reduction Journal.

[51]  C. Treloar,et al.  How to build trustworthy hepatitis C services in an opioid treatment clinic? A qualitative study of clients and health workers in a co-located setting. , 2014, The International journal on drug policy.

[52]  T. Dobbins,et al.  Opioid substitution therapy as a strategy to reduce deaths in prison: retrospective cohort study , 2014, BMJ Open.

[53]  Victorian Ombudsman,et al.  Investigation into deaths and harm in custody , 2014 .

[54]  H. Hansen,et al.  Structural competency: Theorizing a new medical engagement with stigma and inequality , 2014, Social science & medicine.

[55]  C. Chew‐Graham,et al.  A qualitative study of patient choices in using emergency health care for long-term conditions: the importance of candidacy and recursivity. , 2013, Patient education and counseling.

[56]  L. Møller,et al.  The effectiveness of opioid maintenance treatment in prison settings: a systematic review. , 2012, Addiction.

[57]  Barbara Toson,et al.  Effect of prison-based opioid substitution treatment and post-release retention in treatment on risk of re-incarceration. , 2012, Addiction.

[58]  J. Rich,et al.  Overcoming obstacles to implementing methadone maintenance therapy for prisoners: implications for policy and practice. , 2018, Journal of opioid management.

[59]  R. D. Bruce,et al.  Ethical and human rights imperatives to ensure medication-assisted treatment for opioid dependence in prisons and pre-trial detention. , 2008, The International journal on drug policy.

[60]  M. Dixon-Woods,et al.  Conducting a critical interpretive synthesis of the literature on access to healthcare by vulnerable groups , 2006 .

[61]  Andrew Robinson,et al.  Uncovering the Limits of Patient-Centeredness: Implementing a Self-Management Trial for Chronic Illness , 2005, Qualitative health research.

[62]  Paul Farmer,et al.  An Anthropology of Structural Violence1 , 2004 .

[63]  Richard L Kravitz,et al.  Patient trust in the physician: relationship to patient requests. , 2002, Family practice.